These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35474728)

  • 1. Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma.
    Okuyama Y; Hatakeyama S; Numakura K; Narita T; Tanaka T; Miura Y; Sasaki D; Noro D; Tokui N; Okamoto T; Yamamoto H; Narita S; Yoneyama T; Hashimoto Y; Habuchi T; Ohyama C
    BJUI Compass; 2022 Mar; 3(2):154-161. PubMed ID: 35474728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis.
    Liu C; Guo H; Mao H; Tong J; Yang M; Yan X
    Front Oncol; 2022; 12():753234. PubMed ID: 35280736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Association between Baseline Proton Pump Inhibitors, Immune Checkpoint Inhibitors, and Chemotherapy: A Systematic Review with Network Meta-Analysis.
    Chang Y; Lin WY; Chang YC; Huang CH; Tzeng HE; Abdul-Lattif E; Wang TH; Tseng TH; Kang YN; Chi KY
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab.
    Hopkins AM; Kichenadasse G; Karapetis CS; Rowland A; Sorich MJ
    Clin Cancer Res; 2020 Oct; 26(20):5487-5493. PubMed ID: 32933995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Chen B; Yang C; Dragomir MP; Chi D; Chen W; Horst D; Calin GA; Li Q
    Ther Adv Med Oncol; 2022; 14():17588359221111703. PubMed ID: 35860836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
    Deng R; Zhang H; Li Y; Shi Y
    J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
    Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
    Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
    Fukuokaya W; Kimura T; Komura K; Uchimoto T; Nishimura K; Yanagisawa T; Imai Y; Iwatani K; Ito K; Urabe F; Tsuzuki S; Kimura S; Terada N; Mukai S; Oyama Y; Abe H; Kamoto T; Azuma H; Miki J; Egawa S
    Urol Oncol; 2022 Jul; 40(7):346.e1-346.e8. PubMed ID: 35346571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
    Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
    Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of proton pump inhibitor uses on outcomes for cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Li C; Xia Z; Li A; Meng J
    Ann Transl Med; 2020 Dec; 8(24):1655. PubMed ID: 33490167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Impact of Proton Pump Inhibitors on the Efficacy of Immune Checkpoint Inhibitor Combinations in Patients with HBV-Associated Advanced Hepatocellular Carcinoma.
    Wang N; Xu Y; Yang G; Chen H; Wang X; Fu J; Li L; Pan X
    J Hepatocell Carcinoma; 2024; 11():1311-1321. PubMed ID: 38979082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of concomitant proton pump inhibitor use on immune checkpoint inhibitor efficacy among patients with advanced cancer.
    Qin BD; Jiao XD; Zhou XC; Shi B; Wang J; Liu K; Wu Y; Ling Y; Zang YS
    Oncoimmunology; 2021; 10(1):1929727. PubMed ID: 34350061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of the Administration of Antibiotics and Proton Pump Inhibitors in Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma.
    Katsurayama N; Ishihara H; Ishiyama R; Nemoto Y; Ikeda T; Mizoguchi S; Nakayama T; Fukuda H; Yoshida K; Iizuka J; Shinmura H; Hashimoto Y; Kondo T; Takagi T
    Cancer Diagn Progn; 2024; 4(4):496-502. PubMed ID: 38962540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy.
    Zhang L; Chen C; Chai D; Li C; Kuang T; Liu L; Dong K; Deng W; Wang W
    Front Pharmacol; 2022; 13():1018411. PubMed ID: 36225582
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
    Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
    Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
    Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
    Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.